13F filer · CIK 1652044 ↗
Alphabet Inc.
You are looking at Q2 2021. See the latest, Q2 2026 →
Reported value
$4.91B
+98% on the quarter before
Positions
36
8 new · 4 sold out
Top 10
89.2%
of the value
Est. gain
−$134.3M
on stocks held all quarter
Est. return
−6.1%
on those stocks since Q1 2021
Positions as of Jun 30, 2021, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q1 2021. Striped tiles are options.
Largest buys
Since Q1 2021, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- UiPath~$1.97BNew · 0.0% → 40.2%+29,025,785 shares
- Verve Therapeutics Inc~$661.2MNew · 0.0% → 13.5%+10,974,011 shares
- Lyell Immunopharma Inc~$95.3MNew · 0.0% → 1.9%+5,865,125 shares
- Monte Rosa Therapeutics Inc~$33.2MNew · 0.0% → 0.7%+1,464,015 shares
- Vaccitech Plc~$28.6MNew · 0.0% → 0.6%+1,704,444 shares
- Singular Genomics Systems Inc~$17.8MNew · 0.0% → 0.4%+646,622 shares
- Vera Therapeutics Inc~$12.5MNew · 0.0% → 0.3%+944,791 shares
- Relay Therapeutics Inc~$9.5MAdded · 2.2% → 1.4%+258,390 shares
- S&P Global Inc~$243,000New · 0.0% → 0.0%+592 shares
Largest sells
Since Q1 2021, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Upstart~$107.3MSold out · 4.3% → 0.0%−832,423 shares
- Desktop Metal Inc.~$37.4MCut · 8.6% → 2.6%−3,253,708 shares
- Opendoor Technologies Inc~$26.5MSold out · 1.1% → 0.0%−1,250,997 shares
- Airbnb~$25.4MCut · 5.2% → 1.6%−165,986 shares
- Lyft Inc~$17.1MCut · 16.4% → 7.6%−282,831 shares
- Lemonade~$16.5MSold out · 0.7% → 0.0%−177,698 shares
- Sqz Biotechnologies Co~$10.5MCut · 0.5% → 0.0%−727,460 shares
- CrowdStrike~$5.7MSold out · 0.2% → 0.0%−31,020 shares
- Arcus Biosciences Inc~$3.0MCut · 5.3% → 2.6%−109,530 shares
- Rapt Therapeutics Inc~$1.3MCut · 0.7% → 0.5%−42,441 shares
Holdings
As of Jun 30, 2021. Changes are in shares against Mar 31, 2021, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| UiPathCL A · shares New | 40.2% | $1.97B | — | ||||||||
| Verve Therapeutics IncCOM · shares New | 13.5% | $661.2M | — | ||||||||
| Oscar Health IncCL A · shares 0% · price −20.0% | 10.5% | $516.9M | −$129.4M | ||||||||
| Lyft IncCL A COM · shares −4.4% · price −4.3% | 7.6% | $371.2M | −$16.6M | ||||||||
| Dexcom IncCOM · shares 0% · price +18.8% | 7.0% | $344.0M | +$54.5M | ||||||||
| Desktop Metal Inc.COM CL A · shares −23% · price −22.8% | 2.6% | $127.1M | −$37.6M | ||||||||
| Arcus Biosciences IncCOM · shares −2.3% · price −2.2% | 2.6% | $126.7M | −$2.9M | ||||||||
| Lyell Immunopharma IncCOM · shares New | 1.9% | $95.3M | — | ||||||||
| Beam Therapeutics IncCOM · shares −0.8% · price +60.8% | 1.7% | $81.8M | +$30.9M | ||||||||
| AirbnbCOM CL A · shares −24% · price −18.5% | 1.6% | $80.5M | −$18.3M | ||||||||
| Relay Therapeutics IncCOM · shares +16% · price +5.8% | 1.4% | $66.8M | +$3.2M | ||||||||
| Slack Technologies Inc.COM CL A · shares 0% · price +9.0% | 1.2% | $57.6M | +$4.8M | ||||||||
| Sana Biotechnology IncCOM · shares 0% · price −41.3% | 1.1% | $55.3M | −$38.8M | ||||||||
| Clover Health Investments CoCOM CL A · shares 0% · price +76.2% | 1.1% | $54.8M | +$23.7M | ||||||||
| Kronos Bio IncCOM · shares 0% · price −18.2% | 0.70% | $34.4M | −$7.7M | ||||||||
| Monte Rosa Therapeutics IncCOM · shares New | 0.68% | $33.2M | — | ||||||||
| Magenta Therapeutics IncCOM · shares 0% · price −17.4% | 0.67% | $32.7M | −$6.9M | ||||||||
| Vaccitech PlcADS · shares New | 0.58% | $28.6M | — | ||||||||
| Rapt Therapeutics IncCOM · shares −5.1% · price +43.2% | 0.51% | $25.1M | +$7.6M | ||||||||
| Singular Genomics Systems IncCOM · shares New | 0.36% | $17.8M | — | ||||||||
| Ideaya Biosciences IncCOM · shares 0% · price −10.7% | 0.32% | $15.8M | −$1.9M | ||||||||
| Evelo Biosciences IncCOM · shares 0% · price +28.4% | 0.30% | $14.6M | +$3.2M | ||||||||
| Decibel Therapeutics IncCOM · shares 0% · price −24.3% | 0.29% | $14.1M | −$4.5M | ||||||||
| Taysha Gene Therapies IncCOM SHS · shares 0% · price +4.4% | 0.28% | $13.6M | +$577,000 | ||||||||
| Vera Therapeutics IncCL A · shares New | 0.26% | $12.5M | — | ||||||||
| Total · 36 positions | 100% | $4.91B | −$134.3M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q1 2021 to Q2 2021: 28 stocks held throughout, down $134.3M (−6.1%).
- Dexcom Inc+$54.5M+19%
- Beam Therapeutics Inc+$30.9M+61%
- Clover Health Investments Co+$23.7M+76%
- Rapt Therapeutics Inc+$7.6M+43%
- Slack Technologies Inc.+$4.8M+9%
- Lyft Inc−$16.6M−4%
- Airbnb−$18.3M−19%
- Desktop Metal Inc.−$37.6M−23%
- Sana Biotechnology Inc−$38.8M−41%
- Oscar Health Inc−$129.4M−20%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 7, 2026 | $99.08B+2,367% | SEC ↗ |
| Q1 2026 | May 8, 2026 | $4.02B+56% | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | $2.58B+7% | SEC ↗ |
| Q3 2025 | Nov 7, 2025 | $2.41B+13% | SEC ↗ |
| Q2 2025 | Aug 1, 2025 | $2.14B+35% | SEC ↗ |
| Q1 2025 | May 2, 2025 | $1.58B−8% | SEC ↗ |
| Q4 2024 | Feb 7, 2025 | $1.72B−7% | SEC ↗ |
| Q3 2024 | Nov 8, 2024 | $1.84B−7% | SEC ↗ |
| Q2 2024 | Aug 2, 2024 | $1.97B−21% | SEC ↗ |
| Q1 2024 | May 3, 2024 | $2.51B+17% | SEC ↗ |
| Q4 2023 | Feb 9, 2024 | $2.16B+39% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $1.56B−16% | SEC ↗ |
| Q2 2023 | Aug 4, 2023 | $1.86B+3% | SEC ↗ |
| Q1 2023 | May 11, 2023 | $1.80B+5% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $1.72B−12% | SEC ↗ |
| Q3 2022 | Nov 15, 2022 | $1.96B+6% | SEC ↗ |
| Q2 2022 | Nov 15, 2022 | $1.84B−40% | SEC ↗ |
| Q1 2022 | Nov 15, 2022 | $3.08B−26% | SEC ↗ |
| Q4 2021 | Nov 15, 2022 | $4.14B−2% | SEC ↗ |
| Q3 2021 | Nov 15, 2022 | $4.22B−14% | SEC ↗ |
| Q2 2021 | Nov 15, 2022 | $4.91B+98% | SEC ↗ |
| Q1 2021 | Nov 15, 2022 | $2.48B+19% | SEC ↗ |
| Q4 2020 | Nov 15, 2022 | $2.08B−2% | SEC ↗ |
| Q3 2020 | Nov 15, 2022 | $2.13B−2% | SEC ↗ |
| Q2 2020 | Nov 15, 2022 | $2.17B+42% | SEC ↗ |
| Q1 2020 | Nov 15, 2022 | $1.52B−8% | SEC ↗ |
| Q4 2019 | Nov 15, 2022 | $1.65B−50% | SEC ↗ |
| Q3 2019 | Nov 15, 2022 | $3.33B−37% | SEC ↗ |
| Q2 2019 | Nov 15, 2022 | $5.27B+172% | SEC ↗ |
| Q1 2019 | Nov 15, 2022 | $1.94B+129% | SEC ↗ |
| Q4 2018 | Nov 15, 2022 | $845.8M−19% | SEC ↗ |
| Q3 2018 | Nov 15, 2022 | $1.04B−12% | SEC ↗ |
| Q2 2018 | Nov 15, 2022 | $1.19B+94% | SEC ↗ |
| Q1 2018 | Nov 15, 2022 | $614.8M+67% | SEC ↗ |
| Q4 2017 | Nov 15, 2022 | $368.6M+7% | SEC ↗ |
| Q3 2017 | Nov 15, 2022 | $344.0M−1% | SEC ↗ |
| Q2 2017 | Nov 15, 2022 | $347.4M+10% | SEC ↗ |
| Q1 2017 | Nov 15, 2022 | $316.8M+8% | SEC ↗ |
| Q4 2016 | Nov 15, 2022 | $292.8M+6% | SEC ↗ |
| Q3 2016 | Nov 15, 2022 | $275.2M+31% | SEC ↗ |
| Q2 2016 | Nov 15, 2022 | $209.8M−14% | SEC ↗ |
| Q1 2016 | Nov 15, 2022 | $242.9M | SEC ↗ |